Shilpa Medicare Limited Forays into Niche OTC Segment by Launching A Novel Concept of Ready to Dissolve Green Tea Films Under the Brand Name Shilpa's Green T Film in India
August 25, 2020 at 02:34 am
Share
Shilpa Medicare Ltd. announced a new edge, unique and differentiated presentation of Green Tea to Indian Green Tea market, by launch of Shilpa's Green T Films. Shilpa will bring green tea variant in various exciting flavors and is currently available in Ginger and lemon flavor. Shilpa received FSSAI approval for Green Tea Films after sufficiently complying compliance requirements. FSSAI certification is the highest statutory authority that is created to regulate, check and implement science-based standards for the different food products that are manufactured, processed, packed, stored, imported and distributed in the country. FSSAI ensures the availability of healthy and safe product for the consumption of end customers. Shilpa's Green T Films are patent protected and first of this kind in the world. The new generation Shilpa's Green T Films, were designed to be a simple yet an innovative solution for green tea lovers, which will enable an easier and no-mess preparation of green tea any time and every time. There are disadvantages and dissatisfaction with current presentations like tea bags and loose powder, which require lengthy times of brewing, often result in messy and incomplete extraction of useful catechins, all of which make tea bags and loose powder a less preferred alternative. The new easy to prepare Green Tea Films comes as a ready tu dissulve furm in a cunvenient peel, dissolve and drink presentation are best alternative to ready to drink liquid green tea beverages. Shilpa has manufacturing facilities for Green Tea Films at both Hyderabad and Bangalore. The launch of Green Tea films shall cater to the requirements of India however; soon the films will be launched globally upon receipt of required approvals.
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
Shilpa Medicare Limited Forays into Niche OTC Segment by Launching A Novel Concept of Ready to Dissolve Green Tea Films Under the Brand Name Shilpa's Green T Film in India